{"denoms":[{"counts":[{"groupId":"BG000","value":"682"}],"units":"Participants"}],"groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"BG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.10","value":"65.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"301"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"381"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"626"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"669"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"295"}],"title":"0 = Fully active, no restrictions"},{"measurements":[{"groupId":"BG000","value":"319"}],"title":"1 = Restricted activity but ambulatory"},{"measurements":[{"groupId":"BG000","value":"67"}],"title":"2 = Ambulatory and capable of all self-care"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"3 = Limited self-care"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"4 = Completely disabled"}]}],"description":"ECOG performance status is used to describe a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). The scale ranges from 0 to 5: 0 = Fully active, no restrictions; 1 = Restricted activity but ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities; 3 = Limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled, no self-care, confined to bed or chair; 5 = Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.649","value":"6.15"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time since diagnosis","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.713","value":"5.48"}]}]}],"description":"This test measures the amount of a protein called beta-2 microglobulin (B2M) in the blood.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Beta 2 Microglobulin","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"364"}],"title":"Kappa"},{"measurements":[{"groupId":"BG000","value":"230"}],"title":"Lambda"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"No Serum Light chain Type Detected"},{"measurements":[{"groupId":"BG000","value":"72"}],"title":"Test Not Performed"}]}],"description":"Light chains are proteins made by plasma cells and make immunoglobulins (antibodies). Immunoglobulins help protect the body against illness and infections. Immunoglobulins are formed when light chains link up with heavy chains, another type of protein. There are two types of light chains: lambda and kappa light chains. A free light chains test measures the amount of lambda and kappa free light chains in the blood. If the amount of free light chains is higher or lower than normal, it can mean you have a disorder of the plasma cells.","paramType":"COUNT_OF_PARTICIPANTS","title":"Serum Light Chain Type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"145"}],"title":"Immunoglobulin A (IgA)"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Immunoglobulin D (IgD)"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Immunoglobulin E (IgE)"},{"measurements":[{"groupId":"BG000","value":"388"}],"title":"Immunoglobulin G (IgG)"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Immunoglobulin M (IgM)"},{"measurements":[{"groupId":"BG000","value":"68"}],"title":"No serum heavy chain type detected"},{"measurements":[{"groupId":"BG000","value":"72"}],"title":"Test not performed"}]}],"description":"Immunoglobulins help protect the body against illness and infections. Immunoglobulins are formed when light chains link up with heavy chains, another type of protein.","paramType":"COUNT_OF_PARTICIPANTS","title":"Serum Heavy Chain Type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"< 30 mL/min"},{"measurements":[{"groupId":"BG000","value":"57"}],"title":"30 - < 45 mL/min"},{"measurements":[{"groupId":"BG000","value":"168"}],"title":"45 - < 60 mL/min"},{"measurements":[{"groupId":"BG000","value":"190"}],"title":"60 - < 80 mL/min"},{"measurements":[{"groupId":"BG000","value":"250"}],"title":"≥ 80 mL/min"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Renal Function (Cockcroft Gault Creatinine Clearance)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.231","value":"2.43"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Corrected Serum Calcium","unitOfMeasure":"mmol/L"}],"populationDescription":"The intent to treat (ITT) population was defined as all enrolled participants (participants who received an interactive voice response system (IVRS) enrollment date) regardless of whether they received any investigational product (IP) or not."}